CD19 and B-cell chronic lymphocytic leukemia: Clinically, anti-CD19 chimeric antigen receptor (CD19.CAR) T cells reject CLL tumors by overcoming immunological tolerance; however, the efficiency is low compared to other B-cell malignancies (42, 43).